Literature DB >> 22891166

Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.

Deirdre A Lane1, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22891166     DOI： 10.1161/CIRCULATIONAHA.111.060061

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  95 in total

Review 1.  Balancing ischaemia and bleeding risks with novel oral anticoagulants.

Authors:  Usman Baber; Ioannis Mastoris; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

2.  Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.

Authors:  Sandra Lopez-Castaneda; Ignacio Valencia-Hernández; Carlos Arean; Daniel Godínez-Hernández; Martha Eva Viveros-Sandoval
Journal:  Clin Appl Thromb Hemost       Date:  2017-06-15       Impact factor: 2.389

3.  Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

Authors:  Rochelle Sweis; José Biller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

Review 4.  Combining anticoagulation and antiplatelet drugs in coronary artery disease.

Authors:  Jyotsna Janardan; Harry Gibbs
Journal:  Aust Prescr       Date:  2018-08-01

Review 5.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

6.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 7.  Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.

Authors:  Rizma Jalees Bajwa; Lara Kovell; Jon R Resar; Armin Arbab-Zadeh; Kaushik Mandal; Hugh Calkins; Ronald D Berger
Journal:  Clin Cardiol       Date:  2017-07-27       Impact factor: 2.882

Review 8.  Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future.

Authors:  Ramsey M Wehbe; Ajay Yadlapati
Journal:  Tex Heart Inst J       Date:  2016-08-01

9.  National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries.

Authors:  Mukaila A Raji; Matthew Lowery; Yu-Li Lin; Yong-Fang Kuo; Jacques Baillargeon; James S Goodwin
Journal:  Ann Pharmacother       Date:  2013-01-16       Impact factor: 3.154

Review 10.  Adverse drug events as a cause of hospitalization in older adults.

Authors:  Fabio Salvi; Annalisa Marchetti; Federica D'Angelo; Massimo Boemi; Fabrizia Lattanzio; Antonio Cherubini
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.